ACADIA PharmaceuticalsMEX:ACAD 73 3-Year ROIIC % is 74.28 as of Dec. 2025, which is 39% above its 10-year median of 53.59. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN495.48 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 1,320 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 75.61% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ACADIA Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 74.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ACADIA Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
MEX:ACAD's 3-Year ROIIC % is ranked better than 75.61% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs MEX:ACAD: 74.28
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ACADIA Pharmaceuticals 3-Year ROIIC % Related Terms
ACADIA Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ACAD vs VKTX, EWTX, DNLI: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's 3-Year ROIIC % falls into.
ACADIA Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 1887.195 (Dec. 2025) - -4359.228 (Dec. 2022) )
/
( 10070.481 (Dec. 2025) - 2284.989 (Dec. 2022) )
=
6246.423
/
7785.492
=
80.23%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ACADIA Pharmaceuticals (MEX:ACAD) has a 3-Year ROIIC % of 74.28 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ACADIA Pharmaceuticals and its competitors. This is 39% above median its historical median of 53.59. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #322 out of 1320 companies in the Biotechnology industry, placing it in the top 24.4%.
Is ACADIA Pharmaceuticals' 3-Year ROIIC % too high?
ACADIA Pharmaceuticals' current 3-Year ROIIC % of 74.28 is 39% above median its 10-year median of 53.59. Based on the distribution chart, ACADIA Pharmaceuticals ranks #322 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' 3-Year ROIIC % compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #322 out of 1320 companies for 3-Year ROIIC %. This places ACADIA Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current 3-Year ROIIC % is 74.28, which is 39% above median its own 10-year median of 53.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN495.48, compared to a current price of MXN362.00 — trading 26.9% below its estimated fair value. The current 3-Year ROIIC % is 74.28, which is 39% above median its 10-year median of 53.59. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current 3-Year ROIIC % is 74.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN362.00 is trading 26.9% below its estimated GF Value™ of MXN495.48.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:ACAD:
3-Year ROIIC %: 74.28 (39% above median its 10-year median of 53.59)
GF Value™: MXN495.48 vs. price of MXN362.00 (26.9% below fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
